RSVt vaccine

BIOLOGICAL4 trials

Sponsors

Sanofi Pasteur, a Sanofi Company, Sanofi Pasteur Inc.

Conditions

RSV ImmunisationRSV ImmunizationRespiratory Syncytial Virus Respiratory PaediatricsRespiratory Syncytial Virus Infection

Phase 1

Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)

CompletedNCT05687279

Sanofi Pasteur, a Sanofi CompanyRespiratory Syncytial Virus Infection

Start: 2023-02-06End: 2024-12-27Updated: 2026-01-26

Phase 3

Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers

Active, not recruitingPACTR202311725768030

Sanofi Pasteur Inc.Respiratory Syncytial Virus Respiratory Paediatrics

Start: 2024-02-01Target: 1350Updated: 2026-01-27

Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers

TerminatedNCT06252285

Sanofi Pasteur, a Sanofi CompanyRSV Immunisation

Start: 2024-02-06End: 2025-12-04Updated: 2026-02-03

Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers

TerminatedNCT06397768

Sanofi Pasteur, a Sanofi CompanyRSV Immunization

Start: 2024-05-13End: 2025-09-18Updated: 2026-02-03